ClinicalTrials.gg

Program

retatrutide

Also written as “Retatrutide”, “LY3437943” and “Retatrutide (LY3437943)”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, led by 2 companies.

Furthest: phase 3, since May 22, 202333 company-led studies, 11 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly3210 open or runningphase 3since May 22, 2023Feb 13, 2019Nov 2026phase 3 · NCT06662383
Hudson Biotech11 open or runningphase 2since Mar 8, 2026Mar 8, 2026Mar 14, 2027phase 2 · NCT07467447
  • Named in Eli Lilly’s own pipeline as Retatrutide, phase 3, as of Oct 29, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Feb 13, 2019.

  1. Sep 11, 2023Phase 1 study in OverweightEli Lilly · NCT06039826 · 46 enrolled · United States
  2. Feb 8, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06260722 · 1,250 enrolled · United States, Argentina, Canada and more
  3. Mar 1, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06297603 · 320 enrolled · United States, Argentina, Brazil and more
  4. Mar 11, 2024Phase 1 study in ObesityEli Lilly · NCT06313528 · 85 enrolled · United States
  5. Apr 3, 20242 phase 3 studiesEli Lilly · NCT06354660, NCT06383390
  6. Oct 25, 2024Phase 3 study in ObesityEli Lilly · NCT06662383 · 800 enrolled · United States, Argentina, Germany and more
  7. Jan 31, 2025Phase 1 study in HealthyEli Lilly · NCT06808802 · 30 enrolled · Singapore
  8. Feb 28, 2025Phase 3 study in ObesityEli Lilly · NCT06859268 · 643 enrolled · United States, Canada, United Kingdom
  9. May 14, 20252 phase 1 studiesEli Lilly · NCT06982859, NCT06982846
  10. May 28, 2025Phase 3 study in ObesityEli Lilly · NCT07035093 · 586 enrolled · United States, Argentina, Canada and more
  11. Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseEli Lilly · NCT07165028 · 4,500 planned · United States, Argentina, Australia and more
  12. Nov 14, 2025Phase 3 study in ObesityEli Lilly · NCT07232719 · 250 enrolled · United States, United Kingdom
  13. Jan 16, 2026Phase 3 study in ObesityEli Lilly · NCT07357415 · 600 enrolled · United States, Argentina, Canada
  14. Mar 8, 2026Hudson Biotech's first study: phase 2 study in ObesityNew to Hudson BiotechHudson Biotech · NCT07467447 · 300 planned · China

Ahead

  1. Nov 2026Primary completion: phase 3 study in ObesityEli Lilly · NCT06662383
  2. Jan 2027Primary completion: phase 1 study in Diabetes MellitusEli Lilly · NCT06982859
  3. Mar 14, 2027Primary completion: phase 2 study in ObesityHudson Biotech · NCT07467447
  4. Jun 2027Primary completion: phase 3 study in ObesityEli Lilly · NCT07232719

TargetBeta

“Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
UBT251The United Laboratories Internationalphase 312
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07467447Obesity · China2RecruitingHudson BiotechMar 14, 2027300
NCT07357415Obesity · United States, Argentina, Canada3Active, not recruitingEli LillyOct 2028600
NCT07232719Obesity · United States, United Kingdom3Active, not recruitingEli LillyJun 2027250
NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingEli LillyAug 20304,500
NCT07035093Obesity · United States, Argentina, Canada and more3Active, not recruitingEli LillySep 2027586
NCT06982859Diabetes Mellitus · Germany1Active, not recruitingEli LillyJan 202795
NCT06982846Diabetes Mellitus, Type 2 · Austria1CompletedEli LillyMay 4, 202680
NCT06859268Obesity · United States, Canada, United Kingdom3Active, not recruitingEli LillyApr 2028643
NCT06808802Healthy · Singapore1CompletedEli LillyApr 15, 202530
NCT06662383Obesity · United States, Argentina, Germany and more3Active, not recruitingEli LillyNov 2026800
NCT06383390Atherosclerosis · United States, Argentina, Australia and more3Active, not recruitingEli LillyFeb 202910,000
NCT06354660Diabetes Mellitus, Type 2 · United States, India, Mexico and more3CompletedEli LillyJan 22, 2026537
NCT06313528Obesity · United States1CompletedEli LillyAug 26, 202585
NCT06297603Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3Active, not recruitingEli LillyOct 26, 2026320
NCT06260722Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more3Active, not recruitingEli LillyAug 27, 20261,250
NCT06039826Overweight · United States1CompletedEli LillyJul 11, 202446
NCT06003465Healthy · United States1CompletedEli LillyFeb 8, 202457
NCT05959096Healthy · United States1CompletedEli LillyJul 25, 202485
NCT05936151Overweight · United States, Canada, Italy and more2CompletedEli LillyOct 1, 2025146
NCT05931367Obesity · United States, Australia, Canada and more3CompletedEli LillyNov 14, 2025445
NCT05929079Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedEli LillyJun 16, 20261,152
NCT05929066Obesity · United States, Australia, Brazil and more3CompletedEli LillyApr 6, 20262,335
NCT05916560Hepatic Insufficiency · United States1CompletedEli LillyMar 2, 202543
NCT05882045Obesity · United States, Argentina, Australia and more3CompletedEli LillyApr 16, 20261,946
NCT05757531Healthy · United States1CompletedEli LillyJun 23, 20237
NCT05611957Renal Insufficiency · United States1CompletedEli LillySep 5, 202329
NCT05548231Overweight · China1CompletedEli LillyJul 27, 202332
NCT05445232Obesity · United States1CompletedEli LillyFeb 24, 202332
NCT04881760Obesity · United States, Puerto Rico2CompletedEli LillyMay 16, 2022338
NCT04867785Diabetes Mellitus, Type 2 · United States, Puerto Rico2CompletedEli LillyJul 8, 2022281
NCT04823208Diabetes Mellitus, Type 2 · Japan1CompletedEli LillyJun 23, 202264
NCT04143802Diabetes Mellitus, Type 2 · United States1CompletedEli LillyDec 28, 202072
NCT03841630Healthy · Singapore1CompletedEli LillyJul 25, 201945

How it is read

Names in the registry

  • “Retatrutide”, 18 entries
  • “LY3437943”, 14 entries
  • “Retatrutide (LY3437943)”, 1 entry
  • “[¹⁴C]-LY3437943”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.